Novo Nordisk: real-world data reinforces Tresiba's profile.
(CercleFinance.com) - Patients switching to Novo Nordisk's Tresiba experienced significant reductions in blood glucose and lower rates of hypoglycaemia, a real-world study has showed.
A study presented last Saturday at the American Diabetes Association's sessions (ADA) in San Diego showed that people with type-1 diabetes and type-2 diabetes experienced a significant reduction in HbA1c six months after switching to Tresiba from another basal insulin.
According to Novo Nordisk, these results were sustained at 12 months.
Rates of overall hypoglycaemia were also significantly lower at six months after switching to Tresiba, the Danish drugmaker said.
In people with type-1 diabetes, the rate of severe hypoglycaemia was reduced by 85% and by 92% in people with type-2 diabetes.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
A study presented last Saturday at the American Diabetes Association's sessions (ADA) in San Diego showed that people with type-1 diabetes and type-2 diabetes experienced a significant reduction in HbA1c six months after switching to Tresiba from another basal insulin.
According to Novo Nordisk, these results were sustained at 12 months.
Rates of overall hypoglycaemia were also significantly lower at six months after switching to Tresiba, the Danish drugmaker said.
In people with type-1 diabetes, the rate of severe hypoglycaemia was reduced by 85% and by 92% in people with type-2 diabetes.
Copyright (c) 2017 CercleFinance.com. All rights reserved.